Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

IQVIA Holdings Inc. (IQV) — XLV Health Care · S&P 500 Profile |艾昆緯公司介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

IQVIA Holdings Inc. (IQV) — Business, History & S&P 500 Profile |艾昆緯公司介紹

IQVIA company profile · clinical research, health data & analytics · history · financial snapshot · S&P 500 rank #254 · 艾昆緯公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 2, 2026
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
$44.06B
Nov 2, 2026 · StockAnalysis
S&P 500 WEIGHT
0.06%
Rank #254 · Nov 2, 2026 (Slickcharts)
FY2025 TOTAL REVENUES
$16,310M
vs $15,405M in FY2024
FY2025 NET INCOME
$1,360M
Diluted EPS $7.84

SNAPSHOT

TickerIQV (NYSE)
CompanyIQVIA Holdings Inc.
GICS sector / industryHealth Care (XLV) / Life Sciences Tools & Services
S&P 500 rank (by weight)#254 · 0.06% (Nov 2, 2026)
Sector rank (by S&P 500 weight)#33 in Health Care (Nov 2, 2026)
HeadquartersDurham, North Carolina
Founded1982 (Quintiles); IMS Health founded 1954
CEOAri Bousbib (chairman and CEO)
EmployeesApproximately 89,000 (31,000 Technology & Analytics + 51,000 R&D Solutions + 7,000 Contract Sales & Medical)
Market cap$44.06B (Nov 2, 2026)
SEC filingsEDGAR — CIK 0001478242

WHAT IT DOES

IQVIA combines contract clinical research with one of the world’s largest healthcare data sets. Drug developers hire it to run trials and, separately, buy its prescription, claims and real-world data to plan launches, price drugs and target physicians.

Research & Development Solutions — running trials — is the largest segment. Technology & Analytics Solutions sells data, software and analytics on subscription, and Contract Sales & Medical Solutions provides outsourced sales teams.

FY2025 total revenues were $16,310M versus $15,405M in FY2024, net income attributable to IQVIA Holdings Inc. was $1,360M and diluted EPS was $7.84. About 89,000 people work across the three segments.

BUSINESS SEGMENTS — FY2025 REVENUES

SegmentRevenuesShareYoY
Research & Development Solutions$8,896M54.5%—
Technology & Analytics Solutions$6,626M40.6%—
Contract Sales & Medical Solutions$788M4.8%—
YoY shown as — where the 10-K passages do not state a comparable prior-year segment figure; no figure is estimated.

HISTORY

YearMilestone
1954IMS Health founded, building prescription audit data.
1982Quintiles founded as a clinical research organisation.
2016IMS Health and Quintiles merge, forming QuintilesIMS.
2017Renamed IQVIA and listed on the New York Stock Exchange.
2025FY2025 revenues $16,310M, up from $15,405M in FY2024.

COMPETITIVE POSITION

  • Against ICON, Syneos and Thermo Fisher’s clinical businesses in contract research.
  • Against data and analytics rivals including Clarivate, Definitive Healthcare and in-house pharma teams.
  • Scale of data and global trial footprint are the moat; AI tools are now the battleground.
  • Biotech funding cycles drive trial starts and backlog conversion.

FINANCIAL SNAPSHOT — FY2025

Total revenues$16,310M (vs $15,405M in FY2024)
Net income attributable to IQVIA Holdings Inc.$1,360M
Diluted EPS$7.84
EmployeesApproximately 89,000
FY2025 = year ended Dec 31, 2025, per IQVIA Form 10-K filed Feb 17, 2026.

KEY RISKS

  • Biotech funding downturns cutting trial starts and backlog.
  • Data-privacy regulation for patient and prescription data.
  • Customer concentration among large pharmaceutical companies.
  • Currency and emerging-market execution risk on global trials.

WHY IT MATTERS FOR THE S&P 500

IQVIA is the data layer of drug development: its trial backlog and data subscriptions track pharmaceutical R&D spending before it shows up in drug sales.

At S&P 500 rank #254 with a 0.06% weight, it represents life sciences tools and services inside Health Care.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Nov 2, 2026 crawl) · StockAnalysis (market cap — Nov 2, 2026 crawl, single source)
FinancialsIQVIA Form 10-K FY2025 (filed Feb 17, 2026), consolidated statements and segment note
Sector classificationGICS via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

IQVIA

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號IQV(NYSE)
公司IQVIA Holdings Inc.
GICS 板塊/行業健康護理(XLV)/Life Sciences Tools & Services
標普500排名(按權重)第254名 · 0.06%(2026 年 11 月 2 日)
板塊內排名(按標普500權重)健康護理第33名(2026 年 11 月 2 日)
總部北卡羅來納州達勒姆
成立1982年(Quintiles);IMS Health 成立於1954年
行政總裁Ari Bousbib(董事長兼行政總裁)
員工約89,000人(技術與分析31,000人+研發解決方案51,000人+合約銷售與醫療7,000人)
市值$44.06B(2026 年 11 月 2 日)
SEC 文件EDGAR — CIK 0001478242

業務概覽

艾昆緯結合合約臨床研究與全球最大的醫療數據集之一。藥企聘請其執行試驗,同時購買其處方、理賠與真實世界數據,用於規劃上市、定價與醫生覆蓋。

研發解決方案(執行試驗)為最大板塊。技術與分析解決方案以訂閱制銷售數據、軟件與分析;合約銷售與醫療解決方案提供外包銷售團隊。

FY2025 總收入 163.10 億美元,FY2024 為 154.05 億美元;艾昆緯控股公司應佔淨利潤 13.60 億美元,攤薄每股收益 7.84 美元。三個板塊共約 89,000 名員工。

業務板塊 — FY2025 收入

板塊收入佔比同比
研發解決方案$8,896M54.5%—
技術與分析解決方案$6,626M40.6%—
合約銷售與醫療解決方案$788M4.8%—
同比以 — 表示者,為10-K 段落未披露可比上年板塊數字之處;不作估算。

歷史沿革

年份里程碑
1954IMS Health 成立,建立處方審計數據。
1982Quintiles 成立為臨床研究機構。
2016IMS Health 與 Quintiles 合併,組成 QuintilesIMS。
2017更名為 IQVIA,於紐約證券交易所上市。
2025FY2025 收入 163.10 億美元,高於 FY2024 的 154.05 億美元。

競爭地位

  • 合約研究方面對手為 ICON、Syneos 與賽默飛的臨床業務。
  • 數據與分析方面對手包括 Clarivate、Definitive Healthcare 及藥企自有團隊。
  • 數據規模與全球試驗網絡即護城河;AI 工具現為競爭焦點。
  • 生物科技融資周期影響試驗啟動與積壓訂單轉化。

財務快照 — FY2025

總收入$16,310M(FY2024 為 $15,405M)
艾昆緯控股公司應佔淨利潤$1,360M
攤薄每股收益$7.84
員工約89,000人
FY2025 為截至 2025 年 12 月 31 日止年度,據艾昆緯 10-K(2026 年 2 月 17 日提交)。

主要風險

  • 生物科技融資低迷削減試驗啟動與積壓訂單。
  • 患者與處方數據的數據隱私監管。
  • 大型製藥公司客戶集中度。
  • 全球試驗的匯率與新興市場執行風險。

對標普500的重要性

艾昆緯是藥物開發的數據層:其試驗積壓與數據訂閱先於藥品銷售反映製藥研發開支。

標普500排名第254位、權重 0.06%,代表健康護理板塊內的生命科學工具與服務行業。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 11 月 2 日抓取)· StockAnalysis(市值——2026 年 11 月 2 日抓取,單一來源)
財務艾昆緯 FY2025 10-K(2026 年 2 月 17 日提交),合併報表與板塊附註
板塊分類GICS,據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

IQVIA

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · IQV
Data as of Nov 2, 2026 · Financials FY2025 (10-K) · Market data Nov 2026
Previous · Coherent Corp. (COHR) — XLK Information Technology · S&P 500 Profile |相干公司介紹Next · Ventas, Inc. (VTR) — XLRE Real Estate · S&P 500 Profile |文塔斯公司介紹

Entered 2026-11-01 20:11 · updated 2026-11-14 23:40 · rev 5